Skip to main content
Fig. 2 | Critical Care

Fig. 2

From: Septic shock-3 vs 2: an analysis of the ALBIOS study

Fig. 2

Probability of survival from randomization to day 90. a Kaplan–Meier estimates for the probability of survival among patients classified by Sepsis-2 versus Shock-2. Mean survival time 66.7 (95% CI 64.1–69.2) vs 56.4 (95% CI54.1–58.7) days. Log rank test p < 0.001. Absolute 90-day mortality 34.1% vs 46.7%, respectively. Chi-square test p < 0.001. b Kaplan–Meier estimates of Sepsis-3 vs Shock-3. Mean survival time 66.3 (95% CI 64.2–68.4) vs 51.6 (95% CI 48.7–54.5) days. Log rank test p < 0.001. Absolute 90-day mortality 35.0% vs 51.9%, respectively. Chi-square p < 0.001). c Kaplan–Meier estimates for the probability of survival in patients defined by Shock-2, treated with albumin versus crystalloids. Mean survival time 57.9 (95% CI 54.7–61.1) vs 54.9 (95% CI 51.7–58.2). Log rank test p = 0.082. Absolute 90-day mortality 43.5% vs 49.9% (absolute risk reduction 6.3%, risk ratio 0.89, 95% CI 0.79–0.99). Chi-square test p = 0.04. d Kaplan–Meier estimates for the probability of survival in patients defined by Shock-3, treated with albumin versus crystalloids. Mean survival time: 52.9 (95% CI 48.6–57.1) vs 50.4 (95% CI 46.4–54.4). Log rank test p = 0.246. Absolute 90-day mortality 48.7% vs 54.9% (absolute risk reduction 6.2%, risk ratio 0.88, 95% CI 0.75–1.02). Chi-square test p = 0.11

Back to article page